Viking Therapeutics announced it will showcase two posters on its obesity drug VK2735 at The Obesity Society's Annual Meeting, ObesityWeek 2026. The presentations will cover baseline characteristics from the Phase 3 VANQUISH-2 trial and the impact of VK2735 on obesity severity and cardiometabolic parameters from the Phase 2 VENTURE study. VK2735 is a dual GLP-1 and GIP receptor agonist being developed in subcutaneous and oral forms for treating obesity and metabolic disorders. These studies are part of Viking's efforts to develop effective long-term obesity treatments, with Phase 3 trials ongoing.
Viking Therapeutics' obesity drug news provides context for health sector activity on Pluang. For readers following health stocks, 108 of 150 US-listed shares rose while 26 fell as of Nov 09, 2026 18:41 WIB. Notable moves include Inovio Pharmaceuticals Inc (INO) up 11.93% at USD 1.36, Cassava Sciences Inc (FLNA) up 6.01% at USD 0.48, and LifeStance Health Group Inc (LFST) down 5.66% at USD 12.99.
Microsoft will retire the backend services for its UWP Map Control and Windows Maps APIs on November 30, 2026, ending map functionality in many Windows desktop and tablet applications. OnTerra Systems, a Microsoft partner, has developed an off-the-sh...
Marengo Therapeutics presented interim Phase 2 results from the STARt-002 trial combining invikafusp alfa, a selective T-cell agonist, with sacituzumab govitecan in metastatic triple-negative and HR-positive/HER2-negative breast cancer. The trial sho...
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against The Ensign Group, Netcapital Inc., and Webull Corporation. These lawsuits allege misleading statements and failure to di...
Octave Intelligence plc has introduced Octave Attune Facilities, a cloud-based software solution designed to help organizations manage multiple sites with AI-powered tools. This platform integrates building, space, maintenance, and operational data t...
ITT Inc. reported a strong third quarter with revenue up 44% to over $1.40 billion and adjusted earnings rising 20% to $2.26 per share, driven by the SPX FLOW acquisition and 8% organic growth. Orders surged 58%, supported by aerospace, defense, and ...
